Back to search results

UPLYFT for Lymphoma Survivors

This study is testing an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy). UPLYFT aims to help lymphoma survivors with information about survivorship and tools to improve their quality of life and reduce worries about their lymphoma returning. The study wants to see if UPLYFT is practical to use, measured by how many people join, how many complete the sessions, and how much data is collected. You may be able to join if you are 18 or older, have been diagnosed with lymphoma, are in complete remission after your first treatment, and finished treatment 3 to 24 months ago. The study is currently unclear about its recruitment status.

Study design
This is a two-phase pilot study with 74 participants planned. Phase 1 involves feedback from clinicians and a small group of survivors, and Phase 2 is a randomized pilot study.
What's involved
You would participate in 6 weekly intervention sessions. You would also complete baseline assessments and questionnaires.
Compensation
Not stated in the trial record.
Follow-up
The study measures feasibility endpoints for up to 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05080166

UPLYFT For Lymphoma Survivors

Completed
NAAges 18+InterventionalSupportive care
Dana-Farber Cancer Institute
~74 participants
Updated 2026-08-04 on ClinicalTrials.gov
What's tested:Interview with CliniciansField Test of UPLYFT with Lymphoma SurvivorsPilot of UPLYFT with Lymphoma Survivors

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility: Enrollment Rate
Measured over Up to 6 months
+2 more outcomes measured

Conditions

Lymphoma
Survivorship

Explore related trials

Hodgkin's GranulomaNon-Hodgkin Lymphoma

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or classic Hodgkin lymphoma)
Age ≥ 18 years
Interval of 3 months to 24 months from completion of first-line treatment
In complete remission after first line of treatment
Clinically significant FCR (score of ≥ 16 on the validated FCR Inventory-Severity Subscale \[FCRI-SS).
Access to computer (for videoconferencing)
Lymphoma clinicians ≥ 1 year from oncology fellowship completion OR mental health clinicians (psychologists, social workers, psychiatrists) ≥ 1 year from completion of clinical training.
Longitudinal clinical care for patients with lymphoma by oncologists OR provision of care for patients with cancer by mental health clinicians

Exclusion

Age \< 18 years
Concurrent other malignancy
Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorder (as ascertained from medical record screen).
Age \< 18 years
Concurrent other malignancy
Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorders (as ascertained from medical record screen).
Our study will exclude members of the following special populations:
Adults unable to consent
Individuals who are not yet adults (infants, children, teenagers)
Pregnant women
Prisoners

What this trial measures

  • Feasibility: Enrollment RateUp to 6 months

    Proportion of eligible patients approached that enroll in the study.

  • Feasibility: Program Session Completion RateUp to 6 months

    Proportion of study participants randomized to the intervention arm (UPLYFT) who complete all intervention sessions.

  • Feasibility: Data Collection Completion RateUp to 6 months

    Proportion of enrolled participants who complete assigned patient-reported questionnaires during the study.